Navigation Links
Cambrex Receives FDA Warning Letter
Date:8/24/2009

EAST RUTHERFORD, N.J., Aug. 24 /PRNewswire-FirstCall/ -- Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.

The Company has already addressed a number of observations following the inspection and is fully committed to working with the FDA to resolve all of the outstanding issues expeditiously. While the warning letter indicated that until the Company demonstrates that the observations have been corrected, the FDA may withhold approval of new applications or supplements listing the Milan, Italy facility as the API manufacturer, and may deny entry into the U.S. of products manufactured at the site, the Company anticipates satisfactorily responding to the letter within the time period prescribed by the FDA and correcting all observations.

The Company noted that the observations cited in the warning letter pertain only to its Milan, Italy facility and do not relate to its other manufacturing facilities.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit www.cambrex.com.


'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Cambrex Signs Agreement To Acquire ProSyntest AS
3. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
4. Cambrex Customer Announced Recall
5. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
6. Cambrex Presentation at The JPMorgan Healthcare Conference to be Webcast
7. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
8. Cambrex to Announce Fourth Quarter 2008 Financial Results on February 11, 2009
9. Cambrex Reports Fourth Quarter and Full Year 2008 Results
10. Cambrex Regains Compliance With Revised NYSE Listing Standards
11. Cambrex To Announce Second Quarter 2009 Financial Results on August 4, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... ... who like to educate themselves on current issues and who enjoy gaining knowledge on ... to appreciate and love the "Informed" series, hosted by Rob Lowe. A new ... the world. , Running for charity has become a multi-million dollar enterprise ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/23/2017)... ... , ... A recent report from the National Council on Teacher Quality (NCTQ) ... suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions in ... It argues that this higher bar should be set by states, by the Council ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... GENEVA , March 24, 2017 ... revitalizes efforts to develop sutezolid as effective response to ... Day, TB Alliance and the Medicines Patent Pool (MPP) ... sutezolid, an antibiotic drug candidate which demonstrated encouraging results ... of sutezolid in combination with other TB drugs and ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... Repair Procedure By Technique, By Region, By Country (2016-2021)" report ... ... a CAGR of 13.35% during 2016-2021 The strong growth ... in population with heart disease and rising advances in minimally invasive ...
(Date:3/23/2017)... March 23, 2017  The U.S. Food and Drug ... the treatment of adults and pediatric patients 12 years ... those who have not received prior chemotherapy. This is ... aggressive form of skin cancer. "While skin ... with a rare form called Merkel cell cancer have ...
Breaking Medicine Technology: